{"id":962127,"date":"2026-05-13T08:17:43","date_gmt":"2026-05-13T12:17:43","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/tyra-biosciences-reports-first-quarter-2026-financial-results-and-recent-highlights\/"},"modified":"2026-05-13T08:17:43","modified_gmt":"2026-05-13T12:17:43","slug":"tyra-biosciences-reports-first-quarter-2026-financial-results-and-recent-highlights","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/tyra-biosciences-reports-first-quarter-2026-financial-results-and-recent-highlights\/","title":{"rendered":"Tyra Biosciences Reports First Quarter 2026 Financial Results and Recent Highlights"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n – Advanced <\/i>“dabogratinib 3×3<\/i>“\u00a0strategy to pursue 3 late-stage clinical studies in LG-UTUC, IR NMIBC and ACH –<\/i><\/p>\n

\n – First LG-UTUC patient dosed with dabogratinib in SURF303; initial results expected in 2027 –<\/i>\n <\/p>\n

\n – Initial Ph2 data readout from SURF302 expected in August <\/i>
\n 2026\u00a0(n>20 enrolled to date) – <\/i>\n <\/p>\n

\n – Initial Ph2 data readout from safety sentinel cohort in BEACH301 expected in Q4 2026 (4th<\/sup> dose level cleared) –<\/i>\n <\/p>\n

\n – Cash, cash equivalents and marketable securities of $383.5 million at Q1 2026; runway into 2H 2028 –<\/i>\n <\/p>\n

\n CARLSBAD, Calif.<\/span>, May 13, 2026<\/span> \/PRNewswire\/ — Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today reported financial results for the first quarter ended March\u00a031, 2026, and highlighted recent corporate progress.<\/p>\n

“Our dabogratinib ‘3×3’ strategy continues to advance with steady progress across all three programs,” said Todd Harris, Ph.D., Chief Executive Officer of TYRA. “We are taking a differentiated, data-driven approach by aligning our development strategy with the patient journey in FGFR3-driven diseases and conditions. The dosing of the first patient in SURF303 marks an important milestone, as we initiate a potentially registrational study in LG-UTUC that could support TYRA’s first NDA submission. With multiple clinical data readouts expected this year, we remain focused on unlocking the full potential of selective FGFR3 inhibition with oral dabogratinib.”<\/p>\n

Doug Warner, M.D., Chief Medical Officer of TYRA, commented, “In urologic cancers, we see a significant opportunity to address what we believe is a very challenging treatment paradigm for patients that is currently dominated by procedure-based, intravesical therapies. We are developing dabogratinib as a once-daily (QD) oral therapy designed to maintain continuous pressure on the tumor and, if successful, may represent a meaningful shift in how these patients are treated.”<\/p>\n

Dr. Warner continued, “In achondroplasia, we believe our approach with oral dabogratinib may also be transformational. Recently presented data demonstrate that prenatal dosing further delayed premature fusion of synchondroses and increased the area of the foramen magnum. These data expand our perspective on the potential benefits of earlier FGFR3 inhibition as we advance BEACH301. We have now cleared the fourth dose level in our safety sentinel cohort and remain on track to report initial results in the fourth quarter of this year.”<\/p>\n

\n First Quarter and Recent Corporate Highlights<\/b>\n <\/p>\n

\n Dabogratinib 3×3 Strategy<\/b>\n <\/p>\n

In the first quarter of 2026, TYRA advanced its “dabogratinib 3×3” strategy: developing the first orally available, FGFR3 selective inhibitor in 3 future potentially pivotal clinical studies to support regulatory submissions with the aim to commercialize in 3 potential blockbuster indications: LG-UTUC, IR NMIBC and ACH.<\/p>\n